Last checked at 13 Jun 2017 14:40
Shield Therapeutics plc
("Shield" or the "Group")
Result of Annual General Meeting
London, UK, 13 June 2017: Shield Therapeutics plc (LSE:STX), a speciality pharmaceutical company focused on the development and commercialisation of late-stage pharmaceuticals that address unmet medical needs in secondary care, announces that at its Annual General Meeting held today, all resolutions were duly passed.
-Ends-
For further information please contact:
Shield Therapeutics plc | +44 (0) 20 7467 6920 |
Carl Sterritt, Chief Executive Officer Joanne Estell, Chief Financial Officer
| |
Nominated Adviser and Joint Broker | +44 (0)20 3100 2222 |
Liberum Capital Limited | |
Christopher Britton/Steve Pearce
| |
Joint Broker | + 44 (0)20 7418 8900 |
Peel Hunt LLP | |
James Steel/Dr. Christopher Golden
| |
Financial PR Advisor | +44 (0)203 709 5700 |
Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal | shieldtherapeutics@consilium-comms.com |
|
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until the mid-2030's. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com